Beta 3-Adrenergic Receptor (?3-AR) Activation at the End of Sustained Ischemia and/or Early Reperfusion may Prove to be a Valuable Cardioprotective Strategy

Abstract

The contribution of ?3-AR activation towards ischemiareperfusion (IR) damage largely depends on the disease stage, severity, experimental model as well as drug specificities which should be considered when investigating ?3-AR pharmacology for potential therapeutic applications.